TELO (Telomir Pharmaceuticals) Other Financing: $0.85 Mil (TTM As of Mar. 2026)


TELO Telomir Pharmaceuticals Inc TELO
14 GF Score
Price $1.28
! 3 Warning Signs
View Full Analysis

What is Telomir Pharmaceuticals Other Financing?

Telomir Pharmaceuticals TELO +2.42% 14 Other Financing is $0.85 Mil as of Mar. 2026. GuruFocus rates TELO with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Telomir Pharmaceuticals's Other Financing for the three months ended in Mar. 2026 was $-0.16 Mil.

Telomir Pharmaceuticals's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $0.85 Mil.

Telomir Pharmaceuticals Other Financing Historical Data

* Premium members only.

The historical data trend for Telomir Pharmaceuticals's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telomir Pharmaceuticals Other Financing Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
0.00 0.01 1.41 -0.40 0.00

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 1.00 -0.16
TELO
14GF Score
Telomir Pharmaceuticals Inc TELO
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Telomir Pharmaceuticals Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $0.85 Mil mean?
Telomir Pharmaceuticals (TELO) has a Other Financing of $0.85 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Telomir Pharmaceuticals and its competitors.
Is Telomir Pharmaceuticals' Other Financing too high?
Telomir Pharmaceuticals' current Other Financing is $0.85 Mil. Overall, Telomir Pharmaceuticals has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Telomir Pharmaceuticals' Other Financing compare to MAIA and LONA?
Telomir Pharmaceuticals' Other Financing of $0.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Telomir Pharmaceuticals and its competitors. Telomir Pharmaceuticals's current Other Financing is $0.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telomir Pharmaceuticals stock overvalued right now?
Telomir Pharmaceuticals (TELO) has a current Other Financing of $0.85 Mil. The current Other Financing is $0.85 Mil. Telomir Pharmaceuticals' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Telomir Pharmaceuticals (TELO), the current Other Financing is $0.85 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Telomir Pharmaceuticals Business Description

Address 100 SE, 2nd Street, Suite 2000, No.1009, Miami, FL, USA, 33131
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
14GF Score

Get the complete analysis for TELO

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.28
Price